Palliative Radiation — Targeted Symptom Management

Palliative radiation therapy employs high-energy X-rays, gamma rays, or charged particles directed precisely at tumour deposits that are causing severe focal symptoms. The primary clinical intent is symptom palliation rather than long-term disease eradication. Consequently, radiation oncologists typically utilise shorter treatment courses with lower total doses delivered over fewer fractions, minimising time spent in hospital.

Techniques range from conventional external beam radiotherapy to sophisticated methods such as stereotactic body radiotherapy (SBRT). By selectively inducing DNA damage in malignant cells, radiation diminishes tumour bulk. This alleviates mechanical compression on nerves, blood vessels, or adjacent organs, effectively controlling localised symptoms and preserving anatomical integrity.

When cancer spreads, localised complications can severely impair mobility, comfort, and independence. Palliative radiation offers swift, effective relief from bone pain, airway obstruction, spinal cord compression, and ulcerating bleeding tumours. Because treatment schedules are deliberately condensed—often completed in one to ten fractions—patients spend less time travelling to the hospital and endure fewer cumulative side effects, directly supporting their daily comfort and wellbeing.

Eligibility for palliative radiation is determined through cross-sectional imaging, including CT, MRI, or PET-CT scans, which identify the exact structural site causing symptoms. Bone scans help detect skeletal metastases. Routine tissue biomarkers (such as HER2, EGFR, or PD-L1) do not dictate radiotherapy itself, but assist the multidisciplinary team in coordinating radiation alongside ongoing systemic therapies.

Palliative radiation is widely utilised in cancers that metastasise to bones, the brain, or the liver, including breast, prostate, lung, kidney, and thyroid cancers. It is also frequently applied to control symptoms in locally advanced non-small cell lung cancer, oesophageal cancer, and cervical cancer presenting with intractable pelvic haemorrhage.

Palliative radiation can be combined with systemic therapies, though concurrent radiosensitising chemotherapy is often withheld to prevent unnecessary toxicity. It frequently works in tandem with analgesics, often allowing patients to safely reduce their opioid doses once local pain subsides. It is also integrated with orthopaedic stabilisation procedures to secure bones at risk of pathological fracture.